GlassScriptPhysician profile
Arun Rajasekaran
NPI 1386028025
$31,774.76
in general payments reported to CMS, 2019-2025
18 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2022: $73.24 · 2023: $1,585 · 2024: $10K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $5,696 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Food and Beverage: $3,573 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,437.50 |
| Travel and Lodging | $5,696.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Food and Beverage | $3,572.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $13,906.45 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $7,598.38 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $5,565.28 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $3,451.98 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $293.54 | 2025 | Ibsrela, Xphozah 30 Mg |
| Alexion Pharmaceuticals, INC. | $194.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $190.65 | 2025 | Voyxact, Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $132.75 | 2025 | Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $107.63 | 2025 | |
| Amgen INC. | $81.93 | 2025 | Krystexxa, Tavneos |
| Aurinia Pharma U.S., INC. | $62.57 | 2025 | Lupkynis |
| Novo Nordisk INC | $57.60 | 2025 | Wegovy, Ozempic |
| Apellis Pharmaceuticals, INC. | $50.48 | 2025 | |
| Fresenius USA Marketing, INC. | $22.83 | 2025 | Velphoro |
| Scpharmaceuticals INC. | $19.87 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.18 | 2025 | Benlysta |
| Vifor Pharma, INC. | $18.65 | 2025 | Veltassa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Rajasekaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.